Thursday, January 23, 2014
Pharmaceuticals Inc. has opened a new genetics center tasked
with analyzing the genomes of at least 100,000 Geisinger Health System patients
in the next 5 years. The company hopes the volume of data, diversity of the patient
population and rapid validation in humanized mouse models will yield more actionable opportunities than earlier
C. SciBX 7(3);
Published online Jan. 23, 2014
1. McCallister, E. BioCentury
20(51), A1-A4; Dec. 24, 2012
2. Bernstein, K. BioCentury
8(39), A1-A7; Sept. 5, 2000
3. McCallister, E. BioCentury
21(3) A6-A7; Jan. 20, 2014
Amgen Inc. (NASDAQ:AMGN),
Thousand Oaks, Calif.
Baylor College of Medicine, Houston, Texas
Geisinger Health System, Danville, Pa.
Illumina Inc. (NASDAQ:ILMN),
San Diego, Calif.
National Health Service, London, U.K.
National Human Genome Research Institute, Bethesda, Md.
National Institutes of Health, Bethesda, Md.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y.
Sanofi (Euronext:SAN; NYSE:SNY), Paris, France
Yale University, New Haven, Conn.